Wed, Aug 20, 2014, 4:07 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

AmpliPhi Biosciences Corporation Message Board

  • leytonorientfan leytonorientfan Jul 1, 2013 7:18 AM Flag

    Big news today - agreement with US Army

    News just out....

    "AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
    July 01, 2013

    AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).

    The CRADA will focus on developing and commercializing bacteriophage therapeutics to treat Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa infections. The increasing prevalence of antibiotic-resistant bacteria poses a serious threat to public health and military personnel and is a major problem in hospitals and clinics around the world. The initial indication will be wounds and skin infections from S aureus, which is the leading pathogen in healthcare-associated infections in the United States as a whole, accounting for 30.4% of surgical site infections.

    AmpliPhi will retain global regulatory ownership and commercial rights to all products developed as a result of the agreement. USAMRMC will gain access rights to any products developed. WRAIR will be responsible for cGMP production of the lead Staphylococcus product, AmpliPhage-002 for Phase 1 and 2 clinical trials at its Bioproduction Facility. Further details of the agreement including financial terms were not disclosed.

    Philip J. Young, CEO of AmpliPhi, said: “This collaboration is a significant partnership for our company. It combines AmpliPhi’s expertise in the discovery and development of bacteriophage-based therapies with the US Army’s scientific and clinical research for the development of phage therapies for treatment of bacterial infections. It will serve to expedite the development, testing and approval of new treatment modalities.

    etc"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "The initial indication will be wounds and skin infections from S aureus, which is the leading pathogen in healthcare-associated infections in the United States as a whole, accounting for 30.4% of surgical site infections."

      AmpliPhi has been working with Unilever for a few years on skin infection bacteria.

    • Agreed - this news is a significant milestone because one of stated goals Phil Young had when he came aboard and move the company to VA was to secure US government collaborations and grants to further develop biophages, and he did it in a big way.

      APHB just opened the door to the US Army funding their development for years to come. Statement, "If initial development activities are successful, the scope of the collaboration could expand to research and develop bacteriophage therapies against other diseases of mutual interest."

      APHB is also collaborating with the giant consumer products company Unilever ($115 billion Market Cap) to exploit novel genomic information to develop next generation, specific, natural antimicrobials for use in the personal care industry. Addd $ 7 mil. in finanancing, Glybera royalties this Qtr, and a potential CF trial funding partner anyday now and APHB will be trading at significantly higher levels.

      Sentiment: Strong Buy

 
APHB
0.2535-0.0303(-10.68%)3:22 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.